Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 17;26(1):30.
doi: 10.1007/s12017-024-08797-y.

The CD44s Isoform is a Potential Biomarker for Predicting Craniopharyngioma Recurrence in Children

K Bajdak-Rusinek  1 , N Diak  2 , E Gutmajster  3 , A Fus-Kujawa  2 , M Ciupińska  4 , B Kalina-Faska  5 , A Trybus  2   6 , M Grajek  7 , M Kalina  2 , M Mandera  8
Affiliations

The CD44s Isoform is a Potential Biomarker for Predicting Craniopharyngioma Recurrence in Children

K Bajdak-Rusinek et al. Neuromolecular Med. .

Abstract

Adamantinomatous craniopharyngioma (ACP) is an intracranial tumor considered partly malignant due to its ability to infiltrate surrounding structures and tendency to relapse despite radical resection. CD44 is a known stem cell marker in ACP and is upregulated in cell clusters of invasive ACP protrusions; however, the functions of its alternative splicing isoform variants, CD44s and CD44v1-10, have not yet been studied in terms of ACP recurrence, despite their confirmed roles in cancer development and progression. In this study, we first confirmed the difference in total CD44 expression between samples from patients who experienced relapse and those from patients who did not. Moreover, our findings showed that, in recurrent samples, the predominant isoform expressed was CD44s, which might indicate its significance in predicting ACP recurrence. The association between increased CD44 expression and recurrence may lead to the development of prognostic markers of ACP aggressiveness and relapse potential; however, further studies are needed to clarify the exact mechanism of CD44 expression.

Keywords: CD44; Children; Craniopharyngioma; Tumor recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Structure of the CD44 gene. CD44s are encoded by exons (1 to 5) and (16 to 20). Exons 6–15 (v1 to v10) generate CD44 variants through alternative splicing
Fig. 2
Fig. 2
Recurrence-free survival curves for patients with craniopharyngioma after radical excision based on Kaplan‒Meier curve analysis
Fig. 3
Fig. 3
Box plot showing the fold change in CD44 gene expression in patients with (CD44_R) and without (CD44) craniopharyngioma recurrence. ***p < 0.001
Fig. 4
Fig. 4
mRNA expression levels of CD44 isoforms in patients with and without craniopharyngioma recurrence
Fig. 5
Fig. 5
mRNA expression levels of CD44 isoforms in tissue from the primary tumor of patients who experienced recurrence and the relapsed tissue itself
See this image and copyright information in PMC

References

    1. Campanini, M. L., Almeida, J. P., Martins, C. S., & de Castro, M. (2022). The molecular pathogenesis of craniopharyngiomas. Archives of Endocrinology and Metabolism,67(2), 266–275. 10.20945/2359-3997000000600 - PMC - PubMed
    1. Choi, G. H., Kim, G. I., Yoo, J. E., Na, D. C., Han, D. H., Roh, Y. H., Park, Y. N., & Choi, J. S. (2015). Increased expression of circulating cancer stem cell markers during the perioperative period predicts early recurrence after curative resection of hepatocellular carcinoma. Annals of Surgical Oncology,2015(22), S1444-1452. 10.1245/s10434-015-4480-9 - PubMed
    1. Clark, S. W., Kenning, T. J., & Evans, J. J. (2015). Recurrent ectopic craniopharyngioma in the sylvian fissure thirty years after resection through a pterional approach: A case report and review of the literature. Nagoya Journal of Medical Science,77(1–2), 297–306. - PMC - PubMed
    1. Duff, J. M., Meyer, F. B., Ilstrup, D. M., Laws, E. R., Jr., Scleck, C. D., & Scheithauer, B. W. (2000). Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery,46, 291–305. 10.1097/00006123-200002000-00007 - PubMed
    1. Gabay, S., Merchant, T. E., Boop, F. A., Roth, J., & Constantini, S. (2023). Shifting strategies in the treatment of pediatric craniopharyngioma. Current Oncology Reports,25(12), 1497–1513. 10.1007/s11912-023-01471-9 - PubMed

Publication types

LinkOut - more resources